Head-To-Head Review: Palisade Bio (NASDAQ:PALI) & Protara Therapeutics (NASDAQ:TARA)

Palisade Bio (NASDAQ:PALI) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Palisade Bio and Protara Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	0	0	2	0	3.00
Protara Therapeutics	0	0	3	0	3.00

Palisade Bio presently has a consensus target price of $23.00, indicating a potential upside of 1,740.00%. Protara Therapeutics has a consensus target price of $22.67, indicating a potential upside of 413.98%. Given Palisade Bio’s higher probable upside, research analysts plainly believe Palisade Bio is more favorable than Protara Therapeutics.

Valuation and Earnings

This table compares Palisade Bio and Protara Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250,000.00	13.85	-$12.30 million	($13.98)	-0.09
Protara Therapeutics	N/A	N/A	-$40.42 million	($2.82)	-1.56

Palisade Bio has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Palisade Bio and Protara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-148.51%	-115.16%
Protara Therapeutics	N/A	-55.96%	-49.06%

Insider & Institutional Ownership

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 3.3% of Palisade Bio shares are held by company insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Palisade Bio has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Summary

Protara Therapeutics beats Palisade Bio on 7 of the 11 factors compared between the two stocks.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.